Clinical Utility of the Immunocytochemical Detection of p53 Protein in Cytological Specimens

Cancer Research

Volumn 54, Issue 11, 1994, Pages 2914-2918

  Wilson, Philip O G ^c   Delias, Nawal W ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

DIAGNOSIS, DIFFERENTIAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0028363282     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Koss, L.G. Diagnostic cytology and its histopathological basis. Philadelphia: J.B. Lippincott, 1992.
2. Lane, D.P. p. 3, guardian of the genome. Nature (Lond.), 358: 15-16, 1992.
3. Hall, P.A., McKee, P.H., Menage, H.D., Dover, R., and Lane, D.P. High levels of p. 3 protein in UV irradiated normal human skin. Oncogene, 8: 203-207, 1993.
4. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V., et al. Wild type p. 3 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
5. Kastan, M.B., Onyekwere, O., Sidransky, D., et al. Participation of p. 3 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
6. Lin, D., Shields, M.T., Ullrich, S.J., Appella, E., and Mercer, W.E. Growth arrest induced by wild-type p. 3 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. Natl. Acad. Sci. USA, 89: 9210-9214, 1992.
7. Lane, D.P. A death in the life of p. 3. Nature (Lond.), 362: 786-787, 1993.
8. Shaw, P., Bovey, R., Tardy, S., et al. Induction of apoptosis by wild-type p. 3 in human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
9. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p. 3 induces apoptosis of myeloid cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
10. Lane, D.P., and Benchimol, S. Oncogene or anti-oncogene? Genes Dev., 4: 1-8, 1990.
11. Levine, A.J., Momand, J., and Finlay, C.A. The p. 3 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991.
12. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. p. 3 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
13. Nigro, J.M., Baker, S.J., Preisinger, A.C., et al. Mutations in the p. 3 gene occur in diverse human tumour types. Nature (Lond.), 342: 705-708, 1989.
14. Bartek, J., Bartkova, J., Vojtesek, B., et al. Aberrant expression of the p. 3 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6: 1699-1703, 1991.
15. Finlay, C.A., Hinds, P.W., and Levine, A.J. The proto-oncogene p. 3 can act as a suppressor of transformation. Cell, 57: 1083-1093, 1989.
16. Hinds, P., Finlay, C., and Levine, A.J. Mutation is required to activate the p. 3 gene for cooperation with the ras oncogene and transformation. J. Virol., 63: 739-746, 1989.
17. Momand, J., Zambetti, G.P., Olson, D.G., George, D., and Levine, A.J. The mdm-2 oncogene product forms a complex with the p. 3 protein and inhibits p. 3-mediated transactivation. Cell, 69: 1237-1245, 1992.
18. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L., and Vogelstein, B. Amplification of a gene encoding a p. 3-associated protein in human sarcomas. Nature (Lond.), 358: 80-83, 1992.
19. Werness, B.A., Levine, A.J., and Howley, P.M. Association of human papilloma virus types 16 and 18 E6 proteins with p. 3. Science (Washington DC), 248: 76-79, 1990.
20. Milner, J., Metcalf, E.A., and Cook, A.C. Tumour suppressor p. 3: analysis of wild type and mutant p. 3 complexes. Mol. Cell. Biol., 11: 12-19, 1991.
21. Cunningham, J., Lust, J.A., Schaid, D.J., et al. Expression of p. 3 and 17p allelic loss in colorectal carcinoma. Cancer Res., 52: 1974-1980, 1992.
22. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71: 543-546, 1992.
23. Livingstone, L.R., White, A., Sprouse, J., et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p. 3. Cell, 70: 923-935, 1992.
24. Yin, Y., Tainskey, M.A., Bischoff, F.Z., et al. Wild-type p. 3 restores cell cycle control and inhibits gene amplification in cells with mutant p. 3 alleles. Cell, 70: 937-948, 1992.
25. Gannon, J.V., Greaves, R., Iggo, R., and Lane, D.P. Activating mutations in p. 3 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
26. Iggo, R., Gatter, K., Bartek, J., Lane, D.P., and Harris, A. Increased expression of mutant forms of p. 3 oncogene in primary lung cancer. Lancet, 335: 675-679, 1990.
27. Hall, P.A., and Lane, D.P. p. 3 in tumour pathology: can we trust immunohisto-chemistry revisited! J. Pathol., 172: 1-4, 1994.
28. Hall, P.A., Ray, A., Lemoine, N.R., Midgley, C.A., Krausz, T., and Lane, D.P. p. 3 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet, 338: 513, 1991.
29. Bales, C.E., and Durfee, G.R. Cytological techniques. In: L.G. Koss (ed.), Diagnostic Cytology and Its Histopathological Bases, pp. 1451-1515. Philadelphia: J.B. Lippincott, 1992.
30. Vojtesek, B., Bartek, J., Midgley, C.A., and Lane, D.P. An immuno-chemical analysis of the human nuclear phosphoprotein p. 3. New monoclonal antibodies and epitope mapping using recombinant p. 3. J. Immunol. Methods, 151: 237-244, 1992.
31. Midgley, C.A., Fisher, C.J., Bartek, J., Vojtesek, B., Lane, D.P., and Barnes, D.M. Analysis of p. 3 expression in human tumours: an antibody raised against human p. 3 expressed in Escherichia coll J. Cell Sci., 101: 183-189, 1992.
32. Barton, C.M., Staddon, S.L., Hughes, C.M., et al. Abnormalities of the p. 3 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer, 64: 1076-1082, 1991.
33. Dowell, S.P., Lane, D.P., and Hall, P.A. The immunocytochemical detection of p. 3 protein in cytological specimens: technical considerations. Cytopathology, 5: 76-81, 1994.
34. Bishop, J.M. Molecular themes in oncogenesis. Cell, 64: 235-248, 1991.
35. Hunter, T. Cooperation between oncogenes. Cell, 64: 249-270, 1991.
36. Marshall, C.J. Tumour suppressor genes. Cell, 64: 313-326, 1991.
37. Weinberg, R.A. Tumor suppressor genes. Science (Washington DC), 254: 1138-1146, 1991.
38. Barnes, D.M., Hanby, A.M., Gillett, C.E., et al. Abnormal expression of wild type p. 3 protein in normal cells of a cancer family patient. Lancet, 340: 259-263, 1992.
39. Royds, J.A., Stephenson, T.J., Silcocks, P.B., Brammer, H.J., and Shorthouse, A.J. p. 3 protein immunostaining in breast fine needle aspiration cytology. J. Pathol., 170: 207a, 1993.
40. Koutselini, H., Malliri, A., Field, J.K., and Spandidos, D.A. p. 3 expression in cytological specimens from benign and malignant breast lesions. Anticancer Res., 11: 1415-1420, 1991.
41. Vojstek, B., and Lane, D.P. Regulation of p. 3 expression in human breast cancer cell lines. J. Cell Sci., 105: 607-612, 1993.
42. Scarpa, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C., and Hirohashi, S. Pancreatic adenocarcinomas frequently show p. 3 gene mutations. Am. J. Pathol., 142: 1534-1543, 1993.
43. Nuova, K., Soini, Y., Kamel, D., et al. Concurrent p. 3 expression in bronchial dysplasias and squamous cell lung carcinomas. Am. J. Pathol., 142: 725-732, 1993.
44. Soini, Y., Vahakangas, K., Nuorva, K., Kamel, D., Lane, D.P., and Paakko, P. p. 3 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. J. Pathol., 168: 29-33, 1992.
45. Dei-Tos, A.P., Doglioni, C., Laurino, L., Barbareschi, M., and Fletcher, C.D.M. p. 3 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathology, 22: 45-50, 1993.
46. Pignatelli, M., Stamp, G.W., Kafiri, G., Lane, D.P., and Bodmer, W.F. Overexpression of p. 3 nuclear oncoprotein in colorectal adenomas. Int. J. Cancer, 50: 683-688, 1991.
47. Dowell, S., Derias, N., Wilson, P.O.G., Lane, D.P., and Hall, P.A. Expression of p. 3 in reactive mesothelium. Histopathology, 22: 96-97, 1993.
48. Perkins, P., Jin, L., Naylor, B., and Lloyd, R. Comparison of p. 3 immunohistochemical staining of epithelial mesotheliomas and reactive mesothelial proliferations (abstract). Lab. Invest., 68: 341A, 1993.
49. Ramael, M., Lemmens, G., Erdekens, C., et al. Immunoreactivity for p. 3 protein in malignant mesothelioma and non-neoplastic mesothelium. J. Pathol., 168: 371-375, 1992.
50. Mayall, F.G., Goddard, H., and Gibbs, A.R. p. 3 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J. Pathol., 168: 377-381, 1992.
51. Kafiri, G., Thomas, D.M., Shepherd, N.A., Krausz, T., Lane, D.P., and Hall, P.A. p. 3 expression is common in malignant mesothelioma. Histopathology, 21: 331-334, 1992.
52. Zhan, Q., Carrier, F., and Fornace, A.J. Induction of p. 3 activity by DNA damaging agents and growth arrest. Mol. Cell. Biol., 13: 4242-4250, 1993.
53. Barnes, D.M., Dublin, E.A., Fisher, C.J., Levison, D.A., and Millis, R.R. Immunohistological detection of p. 3 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum. Pathol., 24: 469-476, 1993.
54. Allred, D.C., Clark, G.M., Elledge, R., et al. Associations of p. 3 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 85: 200-206, 1993.
55. Yamaguchi, A., Kurosaka, Y., Fushida, S., et al. Expression of p. 3 protein in colorectal cancers and its relationship to short term-prognosis. Cancer (Phila.), 70: 2778-2784, 1992.